200 related articles for article (PubMed ID: 32814714)
21. The transcriptional targets of mutant FOXL2 in granulosa cell tumours.
Rosario R; Araki H; Print CG; Shelling AN
PLoS One; 2012; 7(9):e46270. PubMed ID: 23029457
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary.
D'Angelo E; Mozos A; Nakayama D; Espinosa I; Catasus L; Muñoz J; Prat J
Mod Pathol; 2011 Oct; 24(10):1360-7. PubMed ID: 21623383
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of wild-type but not C134W mutant FOXL2 enhances GnRH-induced cell apoptosis by increasing GnRH receptor expression in human granulosa cell tumors.
Cheng JC; Klausen C; Leung PC
PLoS One; 2013; 8(1):e55099. PubMed ID: 23372819
[TBL] [Abstract][Full Text] [Related]
24. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
25. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG
Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115
[TBL] [Abstract][Full Text] [Related]
26. Genomic exploration of the targets of FOXL2 and ESR2 unveils their implication in cell migration, invasion, and adhesion.
Herman L; Legois B; Todeschini AL; Veitia RA
FASEB J; 2021 Apr; 35(4):e21355. PubMed ID: 33749886
[TBL] [Abstract][Full Text] [Related]
27. An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
Gitto SB; Kim H; Rafail S; Omran DK; Medvedev S; Kinose Y; Rodriguez-Garcia A; Flowers AJ; Xu H; Schwartz LE; Powell DJ; Simpkins F
Gynecol Oncol; 2020 Jan; 156(1):222-232. PubMed ID: 31818495
[TBL] [Abstract][Full Text] [Related]
28. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
[TBL] [Abstract][Full Text] [Related]
29. FOXL2 Mutation Analysis of Ovarian Sex Cord-Stromal Tumors: Genotype-Phenotype Correlation With Diagnostic Considerations.
Buza N; Wong S; Hui P
Int J Gynecol Pathol; 2018 Jul; 37(4):305-315. PubMed ID: 28700438
[TBL] [Abstract][Full Text] [Related]
30. Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes.
Natarajan A; Mayer AT; Xu L; Reeves RE; Gano J; Gambhir SS
Bioconjug Chem; 2015 Oct; 26(10):2062-9. PubMed ID: 26307602
[TBL] [Abstract][Full Text] [Related]
31. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
Front Immunol; 2021; 12():705378. PubMed ID: 34526987
[TBL] [Abstract][Full Text] [Related]
32. [Extraovarian granulosa cell tumor with FOXL2 mutation. Morphological and immunohistochemical differential diagnosis].
Machado I; Martínez Ciarpaglini C; Nieto Morales G; Mata D; Alfonso Ballester R; Muñoz Sornosa E; Ferrandez A
Rev Esp Patol; 2020; 53(2):121-125. PubMed ID: 32199594
[TBL] [Abstract][Full Text] [Related]
33. Rare DICER1 and Absent FOXL2 Mutations Characterize Ovarian Juvenile Granulosa Cell Tumors.
Baillard P; Genestie C; Croce S; Descotes F; Rouleau E; Treilleux I; Gouy S; Morice P; Ray-Coquard I; McCluggage WG; Devouassoux-Shisheboran M
Am J Surg Pathol; 2021 Feb; 45(2):223-229. PubMed ID: 32910017
[TBL] [Abstract][Full Text] [Related]
34. FOXL2
Fuller PJ; Nguyen T; Alexiadis M; Chu S
J Pathol; 2022 Jan; 256(1):1-3. PubMed ID: 34687235
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
Hillman RT; Lin DI; Lawson B; Gershenson DM
Gynecol Oncol; 2021 Sep; 162(3):728-734. PubMed ID: 34238613
[TBL] [Abstract][Full Text] [Related]
36. An alternative miRISC targets a cancer-associated coding sequence mutation in FOXL2.
Shin E; Jin H; Suh DS; Luo Y; Ha HJ; Kim TH; Hahn Y; Hyun S; Lee K; Bae J
EMBO J; 2020 Dec; 39(24):e104719. PubMed ID: 33215742
[TBL] [Abstract][Full Text] [Related]
37. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
[TBL] [Abstract][Full Text] [Related]
38. Aberrant and constitutive expression of FOXL2 impairs ovarian development and functions in mice.
Nicol B; Rodriguez K; Yao HH
Biol Reprod; 2020 Oct; 103(5):966-977. PubMed ID: 32945847
[TBL] [Abstract][Full Text] [Related]
39. Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children.
Kalfa N; Philibert P; Patte C; Ecochard A; Duvillard P; Baldet P; Jaubert F; Fellous M; Sultan C
Fertil Steril; 2007 Apr; 87(4):896-901. PubMed ID: 17430735
[TBL] [Abstract][Full Text] [Related]
40. The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity.
Carles A; Trigo-Gonzalez G; Cao Q; Cheng SG; Moksa M; Bilenky M; Huntsman DG; Morin GB; Hirst M
Cancer Res; 2020 Sep; 80(17):3480-3491. PubMed ID: 32641414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
